The introduction of miR-193b mimetics into nine neuroblastoma cell lines, with distinct genetic characteristics, significantly reduces in vitro cell growth independently of risk factors such as p53 functionality or MYCN amplification. This evidence concerns the gene MYCN and neuroblastoma.